PubMed Health⌕ Search

PubMed · 16553381

The semi-ideal solution theory for mixed ionic solutions at solid-liquid-vapor equilibrium.

Abstract

The semi-ideal solution theory has been presented to describe the changes in thermodynamic properties accompanying the process of mixing the nonideal electrolyte solutions M(i)X(i)-(NY)sat-H2O (i = 1 and 2) at constant activities of NY and H2O, including concentration, chemical potential, activities of all M(i)X(i), Gibbs free energy, enthalpy, entropy, thermal properties, and volumetric properties. The theory states that, under the conditions of equal activities of NY and H2O, the average hydration numbers characterizing the ion-solvent interactions have the same values in the mixture as in the subsystems and the process of mixing these nonideal electrolyte solutions is as simple as that of mixing the ideal solutions if the contributions from the ion-ion interactions to the solvent activity are assumed to be the same in the mixture as in its subsystems, which has been justified by the calculations of the Pitzer equation. Therefore, a series of novel linear equations are established for the thermodynamic properties accompanying the process of mixing these nonideal solutions as well as mixing the ideal solutions M(i)X(i)-(NY)sat-H2O (i = 1 and 2) of equal mole fractions of NY and H2O. From these equations, the widely applied empirical Zdanovskii's rule is derived theoretically, and the important constant in the McKay-Perring equation under isopiestic equilibrium is determined theoretically, which has been substantiated by comparisons with the experimental results for 18 mixtures reported in the literature. Isopiestic measurements have been made for the systems BaCl2-LaCl3-H2O, NaCl-BaCl2-LaCl3-H2O, and NaCl-LaCl3-BaCl2.2H2O(sat)-H2O at 298.15 K. The results are used to test the novel linear concentration relations, and the agreement is excellent. The novel predictive equation for the activity coefficient of M(i)X(i) in M1X1-M2X2-(NY)sat-H2O has been compared with the calculations of the Pitzer equation, and the agreement is good.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Yu-Feng Hu, Shuan-Shi Fan, De-Qing Liang. 2006-03-30. The semi-ideal solution theory for mixed ionic solutions at solid-liquid-vapor equilibrium.. https://doi.org/10.1021/jp0542672

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗